Clinical spectrum of botulism
- PMID: 9585323
- DOI: 10.1002/(sici)1097-4598(199806)21:6<701::aid-mus1>3.0.co;2-b
Clinical spectrum of botulism
Abstract
Botulism is a paralyzing disease caused by the toxin of Clostridium botulinum. The toxin produces skeletal muscle paralysis by producing a presynaptic blockade to the release of acetylcholine. Recent studies have pinpointed the site of action of the several types of botulinum neurotoxin at the nerve terminal. Since the discovery of the toxin about 100 years ago, five clinical forms of botulism have been described: 1) classic or foodborne botulism; 2) wound botulism; 3) infant botulism; 4) hidden botulism; 5) inadvertent botulism. A clinical pattern of descending weakness is characteristic of all five forms. Almost all human cases of botulism are caused by one of three serotypes (A, B, or E). Classic and wound botulism were the only two forms known until the last quarter of this century. Wound botulism was rare until the past decade. Now there are increasing numbers of cases of wound botulism in injecting drug users. Infant botulism, first described in 1976, is now the most frequently reported form. In infant botulism spores of Clostridium botulinum are ingested and germinate in the intestinal tract. Hidden botulism, the adult variant of infant botulism, occurs in adult patients who usually have an abnormality of the intestinal tract that allows colonization by Clostridium botulinum. Inadvertent botulism is the most recent form to be described. It occurs in patients who have been treated with injections of botulinum toxin for dystonic and other movement disorders. Laboratory proof of botulism is established with the detection of toxin in the patient's serum, stool, or wound. The detection of Clostridium botulinum bacteria in the stool or wound should also be considered evidence of clinical botulism. Electrophysiologic studies can provide presumptive of botulism in patients with the clinical signs of botulism. Electrophysiologic testing can be especially helpful when bioassay studies are negative. The most consistent electrophysiologic abnormality is a small evoked muscle action potential in response to a single supramaximal nerve stimulus in a clinically affected muscle. Posttetanic facilitation can be found in some affected muscles. Single-fiber EMG studies typically reveal increased jitter and blocking, which become less marked following activation. The major treatment for severe botulism is advance medical and nursing supportive care with special attention to respiratory status.
Similar articles
-
[Infant botulism and sudden infant death syndrome].Klin Padiatr. 2004 Jan-Feb;216(1):26-30. doi: 10.1055/s-2004-817686. Klin Padiatr. 2004. PMID: 14747968 Review. German.
-
Botulism: update and review.Semin Neurol. 2004 Jun;24(2):155-63. doi: 10.1055/s-2004-830901. Semin Neurol. 2004. PMID: 15257512 Review.
-
Botulism.Clin Infect Dis. 2005 Oct 15;41(8):1167-73. doi: 10.1086/444507. Epub 2005 Aug 29. Clin Infect Dis. 2005. PMID: 16163636 Review.
-
Clostridium botulinum and the ophthalmologist: a review of botulism, including biological warfare ramifications of botulinum toxin.Surv Ophthalmol. 2001 Jul-Aug;46(1):25-34. doi: 10.1016/s0039-6257(01)00227-2. Surv Ophthalmol. 2001. PMID: 11525787 Review.
-
Diversity of the Genomes and Neurotoxins of Strains of Clostridium botulinum Group I and Clostridium sporogenes Associated with Foodborne, Infant and Wound Botulism.Toxins (Basel). 2020 Sep 11;12(9):586. doi: 10.3390/toxins12090586. Toxins (Basel). 2020. PMID: 32932818 Free PMC article.
Cited by
-
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.Toxins (Basel). 2012 Oct;4(10):913-39. doi: 10.3390/toxins4100913. Epub 2012 Oct 19. Toxins (Basel). 2012. PMID: 23162705 Free PMC article. Review.
-
An efficient drug delivery vehicle for botulism countermeasure.BMC Pharmacol. 2009 Oct 27;9:12. doi: 10.1186/1471-2210-9-12. BMC Pharmacol. 2009. PMID: 19860869 Free PMC article.
-
Draft Genome Sequences for Dual-Toxin-Producing Clostridium botulinum Strains.Microbiol Resour Announc. 2019 Jan 24;8(4):e01152-18. doi: 10.1128/MRA.01152-18. eCollection 2019 Jan. Microbiol Resour Announc. 2019. PMID: 30701230 Free PMC article.
-
Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.Appl Environ Microbiol. 2017 Jun 16;83(13):e00642-17. doi: 10.1128/AEM.00642-17. Print 2017 Jul 1. Appl Environ Microbiol. 2017. PMID: 28455330 Free PMC article.
-
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658. Pharmacol Rev. 2017. PMID: 28356439 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous